Statin trial targets hidden heart risk in vasculitis patients
NCT ID NCT02117453
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to see if the drug could lower the risk of future heart attacks or strokes in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rosuvastatin (a statin drug that lowers cholesterol)
- What this could lead to
- If it works, this could point toward a way to reduce heart disease risk in people with ANCA vasculitis.
- What could go wrong
- This is a completed Phase 3 trial, but the results may not show a clear benefit. Statins have known side effects like muscle pain, and the effect on heart events is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED PRIMARY NECROTIZING VASCULITIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug shield kidneys from autoimmune attack?
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders